Study of CM310 in Children Subjects With Moderate-to-severe Atopic Dermatis

Keymed Biosciences Co.Ltd24 enrolled

Overview

This is a multi-center, single arm, open-label study to evaluate safety in children patients with moderate-to severe atopic dermatis.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Atopic Dermatitis

Interventions

CM310BIOLOGICAL

CM310 injection

Eligibility

Sex: ALLMin age: 6 YearsMax age: 11 Years

Medical Language ↔ Plain English

Inclusion Criteria: * With atopic dermatis. * Voluntarily sign the informed consent form. Exclusion Criteria: * Any major surgery planned during the research period. * With intestinal parasitic infection within the first 6 months of screening. * With any previous malignant tumors prior to screening. * With any circumstance that is not suitable to participate in this study.

Locations (1)

Beijing Children's Hospital Capital Medical University

Beijing, China

Outcomes

Primary Outcomes

Adverse events

Incidence of adverse events.

Time frame: up to week 16

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.